Literature DB >> 17688061

Spinal cord injury-induced expression of the antiangiogenic endostatin/collagen XVIII in areas of vascular remodelling.

Christian A Mueller1, Sabine Conrad, Hermann J Schluesener, Torsten Pietsch, Jan M Schwab.   

Abstract

OBJECT: Spinal cord injury (SCI) induces the disruption of neural and vascular structures. In contrast to the emerging knowledge of mechanisms regulating the onset of the postinjury angiogenic response, little is known about counterregulatory signals.
METHODS: Using immunohistochemical methods, the authors investigated the expression of the endogenous angiogenic inhibitor endostatin/collagen XVIII during the tissue remodeling response to SCI.
RESULTS: After SCI, endostatin/collagen XVIII+ cells accumulated at the lesion site, in pannecrotic regions (especially in areas of cavity formation), at the lesion margin/areas of ongoing secondary damage, and in perivascular Virchow-Robin spaces. In remote areas (> 0.75 cm from the epicenter) a more modest accumulation of endostatin/collagen XVIII+ cells was observed, especially in areas of pronounced Wallerian degeneration. The numbers of endostatin/collagen XVIII+ cells reached their maximum on Day 7 after SCI. The cell numbers remained elevated in both, the lesion and remote regions, compared with control spinal cords for 4 weeks afterwards. In addition to being predominantly confined to ED1+-activated microglia/macrophages within the pannecrotic lesion core, endostatin/collagen XVIII expression was frequently detected by the endothelium/vessel walls. Numbers of lesional endostatin/collagen XVIII+ endothelium/vessel walls were found to increase early by Day 1 postinjury, reaching their maximum on Day 3 and declining subsequently to enhanced (above control) levels 30 days after SCI.
CONCLUSIONS: The authors detected that in comparison to the early expression of neoangiogenic factors, there was a postponed lesional expression of the antiangiogenic endostatin/collagen XVIII. Furthermore, the expression of endostatin/collagen XVIII was localized to areas of neovascular pruning and retraction (cavity formation). The expression of endostatin/collagen XVIII by macrophages in a "late" activated phagocytic mode suggests that this factor plays a role in counteracting the preceding "early" neoangiogenic response after SCI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17688061     DOI: 10.3171/SPI-07/08/205

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  5 in total

1.  Quantitative analysis by in vivo imaging of the dynamics of vascular and axonal networks in injured mouse spinal cord.

Authors:  Cyril Dray; Geneviève Rougon; Franck Debarbieux
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-21       Impact factor: 11.205

2.  Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report.

Authors:  Thomas E Ichim; Fabio Solano; Fabian Lara; Eugenia Paris; Federico Ugalde; Jorge Paz Rodriguez; Boris Minev; Vladimir Bogin; Famela Ramos; Erik J Woods; Michael P Murphy; Amit N Patel; Robert J Harman; Neil H Riordan
Journal:  Int Arch Med       Date:  2010-11-11

3.  Temporomandibular joint inflammation activates glial and immune cells in both the trigeminal ganglia and in the spinal trigeminal nucleus.

Authors:  Giovanni Villa; Stefania Ceruti; Matteo Zanardelli; Giulia Magni; Luc Jasmin; Peter T Ohara; Maria P Abbracchio
Journal:  Mol Pain       Date:  2010-12-10       Impact factor: 3.395

4.  Diffusion Tensor Imaging in Diagnosis of Post-Traumatic Syringomyelia in Spinal Cord Injury in Rats.

Authors:  Chao Zhang; Kai Chen; Xiuxin Han; Jiayuanyuan Fu; Patricia Douglas; Anna Y Morozova; Maxim A Abakumov; Ilya L Gubsky; Dejin Li; Jin Guo; Xuening Zhang; Guowen Wang; Vladimir P Chekhonin
Journal:  Med Sci Monit       Date:  2018-01-09

5.  Endostatin/collagen XVIII is increased in cerebrospinal fluid after severe traumatic brain injury.

Authors:  Hao Chen; Li-Xia Xue; He-Li Cao; Shi-Wen Chen; Yan Guo; Wen-Wei Gao; Shi-Ming Ju; Heng-Li Tian
Journal:  Biomed Res Int       Date:  2013-09-08       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.